<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 31, 1999
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________ to _________________
Commission File Number 1-8366
------
POLYDEX PHARMACEUTICALS LIMITED
- ------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Commonwealth of the Bahamas None
- --------------------------------------------- -------------------
(State or other jurisdiction of incorporation (I.R.S. Employer
or organization Identification No.)
421 Comstock Road, Toronto, Ontario, Canada M1L2H5
- ------------------------------------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code (416) 755-2231
--------------
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
Yes X No
---- ----
Indicate the number of shares outstanding of each of the issuer's
classes of common shares, as of the latest practicable date.
Common Shares, $.0167 Par Value 3,016,917 shares
- ------------------------------- ---------------------
(Title of Class) (Outstanding at August 31, 1999)
-1-
<PAGE>
POLYDEX PHARMACEUTICALS LIMITED
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C> <C>
PART I FINANCIAL INFORMATION
Item 1 CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Consolidated Balance Sheets
July 31, 1999 and January 31, 1999......................... 3
Consolidated Statements of Operations
Three Months ended July 31, 1999 and 1998 and
Six Months ended July 31, 1999 and July 31, 1998............5
Consolidated Statements of Shareholders' Equity
Six Months ended July 31, 1999 and 1998.....................6
Consolidated Statements of Cash Flows
Six Months ended July 31, 1999 and 1998.....................7
Segmented Information.......................................8
Item 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS...............9
Item 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK..........................................14
PART II OTHER INFORMATION
Item 4 SUBMISSION OF MATTERS TO A VOTE OF
SECURITY HOLDERS...........................................16
Item 6 EXHIBITS AND REPORTS ON FORM 8-K...........................17
Signatures.................................................18
</TABLE>
-2-
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements.
<TABLE>
<CAPTION>
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
Consolidated Balance Sheets
(Expressed in United States dollars)
=======================================================================================================================
(Unaudited)
July 31 January 31
1999 1999
- -----------------------------------------------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
Current assets:
Cash $ 304,400 $ 655,131
Trade accounts receivable 1,268,471 984,934
Inventories 1,989,409 1,917,278
Prepaid expenses and other current assets 45,164 69,188
----------------------------------------------------------------------------------------------------------------
3,607,444 3,626,531
Property, plant and equipment, net 4,546,692 4,233,144
Patents, net 161,990 166,404
Due from Novadex Corp. - 658,574
Due from shareholder 1,532,251 903,037
Deferred income taxes 528,921 776,000
Other assets 70,602 92,574
- -----------------------------------------------------------------------------------------------------------------------
$ 10,447,900 $ 10,456,264
=======================================================================================================================
</TABLE>
-3-
<PAGE>
<TABLE>
<CAPTION>
=======================================================================================================================
(Unaudited)
July 31 January 31
1999 1999
- -----------------------------------------------------------------------------------------------------------------------
<S> <C> <C>
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Bank indebtedness $ 55,822 $ -
Accounts payable 911,883 1,189,886
Accrued liabilities 495,163 466,556
Loans payable -
Income taxes payable 57,551 51,779
Current portion of long-term debt 153,656 107,994
Current portion of mandatorily redeemable capital stock 125,000 100,000
----------------------------------------------------------------------------------------------------------------
1,799,075 1,916,215
Long-term debt 501,981 521,170
Due to shareholder 659,271 637,017
Deferred gain 656,353 659,018
Deferred income taxes 81,827 148,083
Mandatorily redeemable capital stock 225,000 300,000
- -----------------------------------------------------------------------------------------------------------------------
Total liabilities 3,923,507 4,181,503
Redeemable capital stock (75,899 common shares; 99/01/31 - 93,899) 954,945 1,028,733
Shareholders' equity:
Capital stock:
Authorized:
100,000 A preferred shares of $0.10 each 899,400 B preferred
shares of $0.0167 each 10,000,000 common shares of $0.0167 each
Issued and outstanding:
899,400 B preferred shares 15,010 15,010
2,941,018 common shares (99/01/31 - 2,923,018) 48,852 48,552
Contributed surplus 22,538,271 22,464,783
Deficit (16,295,295) (16,498,775)
Accumulated other comprehensive income (737,390) (783,542)
----------------------------------------------------------------------------------------------------------------
5,569,448 5,246,028
- -----------------------------------------------------------------------------------------------------------------------
$ 10,447,900 $ 10,456,264
=======================================================================================================================
</TABLE>
-4-
<PAGE>
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
Consolidated Statements of Operations (Unaudited)
(Expressed in United States dollars)
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------------------------
Quarter Ended Quarter Ended Year to Date Year to Date
July 31 July 31 July 31 July 31
1999 1998 1999 1998
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Sales $ 3,027,285 $ 2,847,015 $ 6,197,926 $ 5,777,979
Cost of products sold 2,245,541 1,960,032 4,389,648 3,975,314
- -----------------------------------------------------------------------------------------------------------------------------------
781,744 886,983 1,808,278 1,802,665
Expenses:
General and administrative 392,717 410,236 790,525 783,383
Research and development 164,012 32,695 243,516 75,098
Depreciation 126,473 109,276 250,156 217,732
Interest expense 36,653 31,430 71,387 66,336
Selling and promotion 33,151 39,453 52,871 83,949
Amortization 5,479 9,100 10,953 18,172
----------------------------------------------------------------------------------------------------------------------------
758,485 632,190 1,419,408 1,244,670
- -----------------------------------------------------------------------------------------------------------------------------------
Income from operations 23,259 254,793 388,870 557,995
Other income:
Gain on sale of equipment - 577 - 7,246
Interest and other 7,682 22,221 16,300 41,184
----------------------------------------------------------------------------------------------------------------------------
7,682 22,798 16,300 48,430
- -----------------------------------------------------------------------------------------------------------------------------------
Income before the undernoted 30,941 277,591 405,170 606,425
Provision for income taxes (55,393) (174,678) (201,690) (327,499)
- -----------------------------------------------------------------------------------------------------------------------------------
Income (loss) for the period $ (24,452) $ 102,913 $ 203,480 $ 278,926
- -----------------------------------------------------------------------------------------------------------------------------------
Per share information:
Earnings (loss) per common share for the period:
Basic $ (0.01) $ 0.03 $ 0.07 $ 0.09
Diluted $ (0.01) $ 0.03 $ 0.07 $ 0.09
- -----------------------------------------------------------------------------------------------------------------------------------
Weighted average number of common shares
outstanding for the period 3,016,917 2,996,917 3,016,917 2,996,907
- -----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
-5-
<PAGE>
<TABLE>
<CAPTION>
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
Consolidated Statements of Shareholders' Equity and Comprehensive Income (Unaudited)
(Expressed in United States dollars)
========================================================================================================
Year to Date Year to Date
July 31 July 31
1999 1998
- --------------------------------------------------------------------------------------------------------
<S> <C> <C>
Preferred Shares:
Balance, beginning of period $ 15,010 $ 15,010
Private placement of preferred shares - -
-----------------------------------------------------------------------------------------------
Balance, end of period $ 15,010 $ 15,010
========================================================================================================
Common Shares:
Balance, beginning of period $ 48,552 $ 47,283
Sale of shares under purchase contingency 300 -
-----------------------------------------------------------------------------------------------
Balance, end of period $ 48,852 $ 47,283
========================================================================================================
Contributed Surplus:
Balance, beginning of period $ 22,464,783 $ 21,826,025
Sale of shares under purchase contingency 73,488 -
-----------------------------------------------------------------------------------------------
Balance, end of period $ 22,538,271 $ 21,826,025
========================================================================================================
Deficit:
Balance, beginning of period $ (16,498,775) $ (17,071,168)
Net income for the period 203,480 278,926
-----------------------------------------------------------------------------------------------
Balance, end of period $ (16,295,295) $ (16,792,242)
========================================================================================================
Accumulated Other Comprehensive Income:
Balance, beginning of period $ (783,542) $ (665,768)
Currency translation adjustment for the period 46,152 (167,669)
-----------------------------------------------------------------------------------------------
Balance, end of period $ (737,390) $ (833,437)
========================================================================================================
Comprehensive Income for the period:
Net income (loss) for the period $ 203,480 $ 278,926
Currency translation adjustment for the period 46,152 (167,669)
-----------------------------------------------------------------------------------------------
$ 249,632 $ 111,257
========================================================================================================
</TABLE>
-6-
<PAGE>
<TABLE>
<CAPTION>
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
Consolidated Statements of Cash Flows
(Expressed in United States dollars)
===================================================================================================================
Year to Date Year to Date
July 31 July 31
1999 1998
- -------------------------------------------------------------------------------------------------------------------
<S> <C> <C>
Cash provided by (used in):
Operating activities:
Net income for the period $ 203,480 $ 278,926
Add (deduct) items not affecting cash:
Depreciation and amortization 261,109 235,904
Deferred income taxes 190,650 327,499
Loss (gain) on sale of equipment - (7,246)
Legal expenses charged to deferred gain (2,665) (190)
Change in non-cash operating working capital (558,768) (148,677)
------------------------------------------------------------------------------------------------------------
93,806 686,216
------------------------------------------------------------------------------------------------------------
Investing activities:
Additions to property, plant and equipment and patents (537,068) (383,627)
Proceeds from sale of equipment - 7,246
------------------------------------------------------------------------------------------------------------
(537,068) (376,381)
------------------------------------------------------------------------------------------------------------
Financing activities:
Proceeds from loan payable - 18,250
Repayment of long-term debt (50,949) (34,409)
Proceeds from long-term debt 77,422 20,000
Payment of mandatorily redeemable capital stock (50,000) -
Proceeds from (repayment of) advances from shareholder, net 22,254 16,711
Repayment of advances to shareholder, net 29,360 3,010
Increase (decrease) in bank indebtedness 55,822 -
------------------------------------------------------------------------------------------------------------
83,909 23,562
Effect of exchange rate changes on cash 8,622 (44,696)
- -------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash position (350,731) 288,701
Cash, beginning of period 655,131 288,527
- -------------------------------------------------------------------------------------------------------------------
Cash, end of period $ 304,400 $ 577,228
===================================================================================================================
</TABLE>
-7-
<PAGE>
<TABLE>
<CAPTION>
POLYDEX PHARMACEUTICALS LIMITED AND
SUBSIDIARIES
Segmented Information (Unaudited)
(Expressed in United States dollars)
All operations are carried out through Dextran Products Limited ("Dextran") in Canada and through Chemdex, Inc.
("Chemdex") in the United States. The operations of Chemdex represent the veterinary products business and the
operations are carried out through its wholly-owned subsidiary, Veterinary Laboratories, Inc. Each of Dextran
and Chemdex operates as a strategic business unit offering different products. Each subsidiary comprises a
reportable segment as follows:
Dextran - manufactures and sells bulk quantities of Dextran and several of its
derivatives to large pharmaceutical companies throughout the world.
Veterinary products - manufactures and sells veterinary pharmaceutical products and specialty
chemicals in the United States. The primary customers are distributors and
private labelers, who in turn sell to the end-user of these products.
===================================================================================================================================
Quarter Ended Quarter Ended Year to Date Year to Date
July 31 July 31 July 31 July 31
1999 1998 1999 1998
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
SALES:
Dextran $ 1,198,588 $ 1,148,456 $ 2,314,010 $ 2,182,764
Veterinary products 1,828,697 1,698,559 3,883,916 3,595,215
---------------------------------------------------------------------------------------------------------------------------
Total consolidated sales $ 3,027,285 $ 2,847,015 $ 6,197,926 $ 5,777,979
====================================================================================================================================
INCOME FROM OPERATIONS:
Dextran $ 192,082 $ 361,110 $ 567,452 $ 695,295
Veterinary products 13,249 88,492 182,655 227,632
---------------------------------------------------------------------------------------------------------------------------
Total income from operations from segments 205,331 449,602 750,107 922,927
Less: Unallocated corporate expenses 182,072 194,809 361,237 364,932
---------------------------------------------------------------------------------------------------------------------------
Total consolidated income from operations $ 23,259 $ 254,793 $ 388,870 $ 557,995
====================================================================================================================================
ASSETS:
Dextran $ 5,313,001 $ 4,284,096
Veterinary products 4,006,488 3,854,567
---------------------------------------------------------------------------------------------------------------------------
Total assets from segments 9,319,489 8,138,663
Corporate assets 1,128,411 1,755,612
---------------------------------------------------------------------------------------------------------------------------
Total consolidated assets $ 10,447,900 $ 9,894,275
====================================================================================================================================
</TABLE>
-8-
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations.
(a) RESULTS OF OPERATIONS
During the fiscal quarter ended July 31, 1999, the Registrant's pre-tax
income from operations amounted to $23,259, as compared to $254,793 for the
same period last year. This decline in results is due to a decrease in
operating profits during the quarter at Dextran Products Limited ("Dextran")
of $169,028, and at Veterinary Laboratories Inc. ("Vet Labs") of $75,243. The
decline in operating profits at both Dextran and Vet Labs is primarily
attributable to a reduction in margins, due primarily to product mix
discussed below, and a significant increase in research and development
expenditures as compared to the same quarter last year.
Sales volume for the second quarter increased from $2,847,015 to $3,027,285,
representing an increase of $180,270. This increase in sales volume is
attributable to an increase at Vet Labs of $130,138 and an increase at
Dextran of $50,132. The injectable and liquid product lines accounted for the
entire quarter over quarter sales increase at Vet Labs. Similar to first
quarter this year, there was a significant product mix variance within the
injectable product line. As in the first quarter this year, injectable iron
dextran sales declined from the second quarter last year, however this
reduction was more than offset by increased sales of other injectable vitamin
products. Vet Labs continues to increase its market penetration with these
new injectable vitamin products as well as the liquids product line. Sales at
Dextran increased quarter over quarter due to increased demand for iron
dextran.
The decline in injectable iron dextran sales is due to two factors. The first
factor is the significant decline in hog production due in part to the Asian
financial crisis. Asia has significantly reduced imports of hogs, which has
forced North American hog producers to reduce their production. Management
expects to see an increase in hog production in the coming quarter as the
Asian crisis is beginning to ease. The second reason for this decline in
sales of injectable iron dextran is that a new competitor has entered the
market. This competitor has not had a significant impact, but has taken a
small portion of the market. Management's strategy to deal with competition
has been to diversify the product lines at Vet Labs. This has been successful
with the introduction of the injectable vitamin products. The development of
new products to add to the diversification of the product lines is continuing.
Gross margins decreased from 31% in the second quarter last year to 26% this
quarter. Dextran's quarter over quarter gross margin decreased slightly from
41% to 40% while Vet Labs' gross margin decreased from 18% to 15%. The
decrease in margin at Vet Labs is attributable to the decrease in injectable
iron dextran sales. This is one of the highest margin products at Vet Labs.
Liquids are generally a lower margin product line. In the past, this decline
in sales of injectable iron dextran would have had a much worse impact on
margins, however the diversification of the product line with the addition of
the injectable vitamin products has helped considerably in maintaining
margins.
-9-
<PAGE>
Management's on-going plan to develop new products and increase the product
offering should continue to improve and stabilize the overall margin levels
at Vet Labs. The gross margin achieved at Vet Labs this quarter is consistent
with that experienced in the first quarter this year. The gross margin
achieved at Dextran this quarter is lower than that realized in first quarter
this year due to a product mix variance. In first quarter, there were very
strong sales of higher margin iron dextran product. The sales were not as
skewed to this product in the second quarter.
Management expects strong sales and margins to continue at Dextran. As
expected, summer months are typically slower sales months for Vet Labs as
large animals are put outdoors to pasture and therefore have less need for
vitamins and other supplements. Management is therefore forecasting higher
sales levels in the third quarter than were achieved in the second quarter at
Vet Labs. Management also expects some recovery in the hog markets in the
coming quarter and therefore is forecasting higher injectable iron dextran
sales. This is expected to improve margins slightly at Vet Labs as well.
General and administrative expenses have decreased by $17,519 this quarter as
compared to the same quarter last year, primarily due to a reduction in
salary expense due to the departure of the former President of Chemdex, Inc.,
Natu Patel, in the third quarter last year.
Research and development costs increased by $131,317 as compared to the first
quarter last year due to an increase in new product development costs
relating to the development of a raw material for a human injectable product.
Development costs to date relating to this project total approximately
$179,000. Development costs for this product are expected to continue for the
remainder of the year.
Research and development, in conjunction with the Rush Institute of the
University of Chicago, relating to Cellulose Sulfate gel is progressing. The
U.S. Food & Drug Administration has approved an Investigational New Drug
(IND) exemption for Phase I human clinical trials to test the safety and
tolerance of this gel. A nine-month trial, funded by The Consortium for
Industrial Collaboration in Contraceptive Research, has started. Pre-IND
tests have indicated that this gel holds great promise as a topical
prophylactic for sexually transmitted diseases, including AIDS, and as a
contraceptive.
Depreciation expenses have increased by $17,197 primarily due to the
acquisition of new equipment at Dextran.
There was no significant quarter over quarter change in interest expense,
selling and promotion expenses or amortization expense.
Operating results for the second quarter ended July 31, 1999 are not
necessarily indicative of the results that may be expected for the year ended
January 31, 2000. For further information, refer to the consolidated
-10-
<PAGE>
statements and footnotes thereto included in the Registrant's annual report
on Form 10-K for the year ended January 31, 1999.
(b) LIQUIDITY AND CAPITAL RESOURCES
During the second quarter, the Registrant generated cash flow from operations
of $19,347 compared to the prior year second quarter cash flow from
operations of $497,964. This decrease is attributable to the decrease in net
income for the quarter as compared to the prior year, and the decrease in
payables during the quarter. In addition, the Registrant experienced a large
decrease in receivables during the second quarter last year, which
contributed to the large increase in non-cash operating working capital. The
decrease in payables is primarily attributable to the payment of
refurbishment costs in the quarter.
There were no significant changes in inventory levels at either Dextran or
Vet Labs during the quarter.
The majority of capital expenditures on plant and equipment during the
quarter related to engineering and construction costs for a new piece of
production equipment at Dextran. To date, plant refurbishment costs have been
funded from working capital, however financing arrangements have been
negotiated with Dextran's bank to finance a large piece of production
equipment. The construction of this piece of production equipment will
continue in the third quarter and installation is planned for fourth quarter.
There are no production interruptions planned for the next quarter due to
this refurbishment, however there could be some production interruption in
the fourth quarter during the installation of this equipment.
Management has arranged bank financing for the construction of a new
warehouse at Vet Labs. The planning and engineering phase has commenced.
During the quarter, Novadex Corp., a company owned by the major shareholder
of the Registrant, was liquidated. All assets and liabilities of Novadex
Corp. were assumed by the major shareholder of the Registrant on the same
terms and conditions. The transfer of the balance receivable from Novadex
Corp. to the due from shareholder account has not been reflected in the
statement of cash flows as it is a non-cash transaction. Included in the
assets assumed by the major shareholder of the Registrant is an exclusive
worldwide license agreement with the Registrant to use a certain process for
producing iron dextran. The Registrant will now pay this license fee to the
major shareholder. These payments will be applied to the balance owing by the
major shareholder.
At the beginning of the year, two critical long-term objectives were
identified.
1. Bring new products to market. During the first six months of the year,
Cellulose Sulfate has commenced Phase I human clinical trials,
development work has commenced on a raw material for a human
-11-
<PAGE>
injectable product and Vet Labs continues development of new veterinary
products.
2. Upgrade and refurbish existing production facilities to increase capacity
and efficiency. Refurbishment of the Dextran plant has commenced along
with construction of new production equipment. Planning has commenced for
a new warehouse facility at Vet Labs.
(c) YEAR 2000
The year 2000 issue refers to computer programs being written using two
digits rather than four to define an applicable year. A company's hardware,
date driven automated equipment or computer programs that have a two digit field
to define the year may recognize a date using "00" as the year 1900 rather than
the year 2000. This faulty recognition could result in a system failure,
disruption of operations, or inaccurate information or calculations. Similar to
other companies, the Registrant faces the challenge of ensuring that all of our
computer related functions will work properly from the year 2000 and beyond.
Management has completed a detailed assessment of the Registrant's systems,
and does not believe that the year 2000 computer issue will have a material
adverse effect on the its core business operations. Management expects
transactions with customers, suppliers, corporate partners and financial
institutions to be fully supported by the Registrant's systems.
While management believes its planning and preparations will be adequate
and complete will in advance of the year 2000, there can be no assurance that
the systems of suppliers and other companies on which the Registrant relies will
be year 2000 compliant on a timely basis, or that such failures by third parties
will not have a material adverse effect on the Registrant's business, results of
operations and financial condition. Management is in the process of developing
contingency plans that focus on reducing any disruption that might be created by
third parties with whom the Registrant does business being year 2000
noncompliant. Management does not expect the cost of its year 2000 initiative
to be material to the Registrant's results of operations or financial condition.
-12-
<PAGE>
FORWARD-LOOKING STATEMENTS SAFE HARBOR
This Form 10-Q, including the Management's Discussion and Analysis of
Financial Condition and Results of Operations, contains various
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, which represent the Company's expectations
or beliefs concerning future events, including, but not limited to statements
regarding management's expectations of regulatory approval and the
commencement of sales and the sufficiency of the Company's cash flow for the
Company's future liquidity and capital resource needs. In addition,
statements containing expressions such as "believes", "anticipates" or
"expects" used in this Form 10-Q, the Company's Annual Report, and the
Company's periodic reports on Forms 10-K and 10-Q previously filed with the
Securities and Exchange Commission are intended to identify forward-looking
statements. The Company cautions that these and similar statements in this
Form 10-Q, the Company's Annual Report, and in previously filed periodic
reports including reports filed on Forms 10-K and 10-Q are further qualified
by important factors that could cause actual results to differ materially
from those in the forward-looking statements. These factors include, without
limitation, changing market conditions, the progress of clinical trials, and
the results obtained, the establishment of new corporate alliances, the
impact of competitive products and pricing, and the timely development, FDA
approval and market acceptance of the Company's products, none of which can
be assured. Results actually achieved may differ materially from expected
results included in these statements as a result of these or other factors.
The accompanying unaudited condensed consolidated financial statements have
been prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-Q and
Article 10 of Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management,
all adjustments (consisting of normally recurring accruals) considered
necessary for a fair presentation have been included.
-13-
<PAGE>
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
POLYDEX PHARMACEUTICALS LIMITED
JULY 31, 1999
INTEREST RATE SENSITIVITY
The table below provides information about the Company's financial
instruments that are sensitive to changes in interest rates. All financial
instruments are held for other than trading purposes. The Company does not
have a material exposure to interest rate risk.
The table presents principal cash flows and related weighted average
interest rates by expected maturity dates.
<TABLE>
<CAPTION>
Expected Maturity Date
----------------------------------------------------------------- Fair
31-Jan-00 31-Jan-01 31-Jan-02 31-Jan-03 31-Jan-04 Thereafter Total Value
--------- --------- --------- --------- --------- ---------- -------- -------
(US$ Equivalent)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
ASSETS
Notes receivable:
Variable rate ($US) 68,518 66,979 18,201 19,611 21,131 599,111 793,551 793,551
Average interest rate 7.58% 7.66% 7.75% 7.75% 7.75% 7.75% 7.71%
LIABILITIES:
Long-term debt:
Fixed rate ($US) 16,980 348,332 - - - - 365,312 365,312
Average interest rate 8.80% 8.79% 0.00% 0.00% 0.00% 0.00% 8.79%
Fixed rate ($CDN) 49,020 97,578 113,652 6,653 - - 266,902 266,902
Average interest rate 9.01% 9.06% 9.04% 12.00% 0.00% 0.00% 9.78%
Variable rate ($US) 5,453 (40,608) (43,756) (47,147) (50,800) 861,129 684,271 684,271
Average interest rate 8.31% 7.75% 7.75% 7.75% 7.75% 7.75% 7.84%
</TABLE>
-14-
<PAGE>
POLYDEX PHARMACEUTICALS LIMITED
JULY 31, 1999
EXCHANGE RATE SENSITIVITY
The table below provides information about the Company's financial
instruments that are sensitive to changes in foreign currency exchange
rates. All financial instruments are held for other than trading purposes.
The Company's major exposure to exchange rate risk is that the Canadian
dollar rises dramatically in relation to the U.S. dollar and that this
significantly reduces the gross margin experienced at Dextran Products.
Management monitors the margin at Dextran to ensure that an acceptable
margin level is maintained. Management has the ability, to some extent, to
adjust sales prices to maintain an acceptable margin level.
The table presents principal cash flows and related weighted average
interest rates by expected maturity dates.
<TABLE>
<CAPTION>
Expected Maturity Date
----------------------------------------------------------------- Fair
31-Jan-00 31-Jan-01 31-Jan-02 31-Jan-03 31-Jan-04 Thereafter Total Value
--------- --------- --------- --------- --------- ---------- -------- -------
(US$ Equivalent)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
LIABILITIES:
Long-term debt:
Fixed rate ($CDN) 49,020 97,578 113,652 6,653 - - 266,902 266,902
Average interest rate 9.01% 9.06% 9.04% 12.00% 0.00% 0.00% 9.78%
</TABLE>
-15-
<PAGE>
PART II - OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders.
(a) The 1999 Annual General Meeting of the Members was held
on June 24, 1999.
(b) Not applicable.
(c) At the Annual Meeting, Mr. Derek John Michael Lederer and
Ms. Ruth L. Usher were elected as directors of the Company to
hold office for a three-year term expiring at the Annual
General Meeting of the Members held in 2002 or until
successors are duly elected and qualified. The tabulation of
votes in person or by proxy at the Annual Meeting with respect
to Mr. Lederer's and Ms. Usher's election are as follows:
<TABLE>
<CAPTION>
Against or Abstentions and
Class For Withheld Non-Votes
----- --- ---------- ----------
<S> <C> <C> <C> <C>
Lederer Common Shares 2,315,479 77,658 623,780
Class B Preferred 899,400 -- --
Shares
Usher Common Shares 2,303,798 101,220 623,780
Class B Preferred 899,400 -- --
Shares
</TABLE>
The Shareholders of the Company also approved proposals to:
(i) amend the Articles of Association to set the voting power
of the Company's Class B Preferred Shares at two votes per
share ("Proposal No. 2"), and (ii) amend the Articles of
Association to increase the authorized Common Shares of the
Company from four million to ten million Common Shares
("Proposal No. 3"). The tabulation of votes present in person
or by proxy at the Annual Meeting with respect to the
foregoing proposals are as follows:
-16-
<PAGE>
<TABLE>
<CAPTION>
Against or Abstentions and
Class For Withheld Non-Votes
----- --- ---------- ----------
<S> <C> <C> <C> <C>
Proposal No. 2 Common Shares 1,007,183 263,433 1,746,301
Class B Preferred 899,400 -- --
Shares
Proposal No. 3 Common Shares 2,178,552 201,053 637,312
Class B Preferred 899,400 -- --
Shares
</TABLE>
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
3.1 Memorandum of Association of Polydex Pharmaceuticals
Limited, as amended to date (filed as Exhibit 3.1 to
the Annual Report on Form 10-K filed April 30, 1997,
and incorporated herein by reference)
3.2 Articles of Association of Polydex Pharmaceuticals
Limited, as amended to date
27 Financial Data Schedule
(b) Reports on Form 8-K
Not applicable.
-17-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: September 13, 1999
POLYDEX PHARMACEUTICALS LIMITED
(Registrant)
By \s\ George G. Usher
-----------------------------
George G. Usher, Chairman, President
and Chief Executive Officer
(Principal Executive Officer)
By \s\ Sharon L. Wardlaw
-----------------------------
Sharon L. Wardlaw, Treasurer, Secretary
and Chief Financial and Accounting
Officer
(Principal Financial Officer)
-18-
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Number Exhibit Description
- -------------- -------------------
<S> <C>
3.2 Amended Articles of Association of Polydex
Pharmaceuticals Limited
27 Financial Data Schedule
</TABLE>
<PAGE>
Exhibit 3.2
CERTIFICATE AS TO
CORPORATE RESOLUTION
OF
POLYDEX PHARMACEUTICALS LIMITED
REGISTRATION NO.: 24,178
I, Sharon L. Wardlaw, Secretary of Polydex Pharmaceuticals Limited,
DO HEREBY CERTIFY that the following is a true and correct copy of
Resolutions passed by a majority vote of the Shareholders of Polydex
Pharmaceuticals Limited (the "Company") at a meeting held on the 24th day of
June, 1999:
RESOLVED:
1. That Article 2(d)(2) of the Articles of Association of the
Company be amended by deleting the present Article 2(d)(2) in
its entirety and substituting therefor the following new
Article 2(d)(2):
(2) the Class B Preferred Shares shall bestow upon
the holders thereof the right of two votes per share,
which may be increased incrementally up to five votes
per share upon the consent of the holders of a
majority-in-interest of the Common Shares and the
Class B Preferred Shares.
2. That Article 2(a) of the Articles of Association of the
Company be amended by deleting the present second paragraph of
Article 2(a) in its entirety and substituting therefore the
following new second paragraph of Article 2(a):
The authorized share capital of the Company
is U.S. $187,650 divided into 10,000,000 Common
Shares of $0.016 par value each, 100,000 Class A
Preferred Shares of $0.10 par value each, and 899,400
Class B Preferred Shares of $0.016 par value each.
Dated the 25th day of June, 1999.
POLYDEX PHARMACEUTICALS LIMITED
/s/ Sharon L. Wardlaw
- -------------------------------
Sharon L. Wardlaw, Secretary
<PAGE>
CERTIFICATE AS TO
CORPORATE RESOLUTION
OF
POLYDEX PHARMACEUTICALS LIMITED
REGISTRATION NO.: 24,178
I, Sharon L. Wardlaw, Secretary of Polydex Pharmaceuticals Limited, DO
HEREBY CERTIFY that the following is a true and correct copy of Resolutions
passed by a majority vote of the Shareholders of Polydex Pharmaceuticals Limited
(the "Company") at a meeting held on the 19th day of June, 1998:
RESOLVED:
1. That the present Article 2 of the Articles of Association of
the Company be amended by relettering subsections (d) and (e)
to read as subsection (e) and (f), respectfully, and adding
the following new Article 2 subsection (d):
SHARE CAPITAL:
2. (d) The Class B Preferred Shares shall have the following
rights and characteristics, that is:
1 The Class B Preferred Shares shall bestow
upon the holders thereof no rights in
respective dividends, shall bestow no rights
in respect of convertibility into any other
class of shares and, in winding up of the
corporation, shall rank behind both the
Class A Preferred Shares and the Common
Shares;
2 The Class B Preferred Shares shall bestow
upon the holders the right of one vote per
share, which may be increased to five votes
per share upon the consent of the majority
of the holders of the Common Shares and the
Class B Preferred Shares.
2. That Article 33 of the Articles of Association of the Company
be amended by deleting the second sentence of Article 33 in
its entirety and substituting therefore the following new
second sentence of Article 33:
-1-
<PAGE>
Except as maybe otherwise required by law, a quorum for the
transaction of business at any general meeting of the members
shall be members present wholly or represented by proxy
between them not less than one-third (1/3) of all Common
Shares which are issued at the date not more than sixty (60)
days prior to the date of the meeting fixed as a record date
by the directors and which entitle the holder thereof to vote.
Dated the 20th day of June, 1998.
POLYDEX PHARMACEUTICALS LIMITED
\s\ Sharon L. Wardlaw
- -------------------------------
Sharon L. Wardlaw, Secretary
-2-
<PAGE>
AMENDED CERTIFICATE AS TO
CORPORATE RESOLUTION
OF
POLYDEX PHARMACEUTICALS LIMITED
Registration No.: 24,178
I, Sharon Wardlaw, Secretary of Polydex Pharmaceuticals Limited, DO
HEREBY CERTIFY that the certificate issued by me on the 19th June 1997 contained
a clerical error in referring to the par value of the Common Shares and that
this Certificate issued in lieu thereof sets out as follows a true and correct
copy of resolutions passed by a majority vote of the Shareholders of Polydex
Pharmaceuticals Limited (the "Company") at a meeting held on the Nineteenth day
of June, 1997:-
RESOLVED:
1. That the Articles of Association of the Company be amended by
the deletion of the first paragraph of Article 2(a) in its
entirety and the substitution thereof of the following first
new paragraph of Article 2(a):-
SHARE CAPITAL
2(a) The Capital of the Company is $91,650,000 in the
currency of the United States of America divided into
100,000 "A" Preferred Shares of $0.10 par value each,
899,400 "B" Preferred Shares of $0.016 (the 6 recuring)
par value each and 4,000,000 Common Shares of $0.016
(the 6 recuring) par value each and such "A" Preferred
Shares shall confer upon their holders the following
rights, that is:
2. That the Articles of Association of the Company be amended by
the deletion of the first paragraph of Article 53 in its
entirety and the substitution thereof of the following new
first paragraph of Article 53:
-1-
<PAGE>
DIRECTORS
---------
Subject as hereinafter provided the Directors shall not
be less than three nor more than nine in number. The first
Directors shall be appointed at the first general meeting of
the members and their number shall be within the limits
above-mentioned. The Company may by ordinary resolution from
time to time increase or reduce the maximum or minimum number
of Directors.
Dated the twentieth day of June, 1997.
POLYDEX PHARMACEUTICALS LIMITED
By: /s/ Sharon Wardlaw
----------------------------------
Sharon Wardlaw
Secretary
-2-
<PAGE>
CERTIFIED COPY OF CORPORATE RESOLUTION
OF
POLYDEX PHARMACEUTICALS LIMITED
Registration No.: 24,178
I, Sarah M. Lobosky, Assistant Secretary of Polydex Pharmaceuticals Limited, DO
HEREBY CERTIFY that the following is a true and correct copy of resolutions
passed by a majority vote of the Shareholders of Polydex Pharmaceuticals Limited
(the "Company") at a meeting held on the Twenty-ninth day of September, A.D.,
1995;
RESOLVED:
1. That the authorized share capital of the Company be increased from
US$81,650.00 divided into 40,000,000 Common Shares of $0.0016 (the 6 recurring)
par value each, 1,000,000 "A" Preferred Shares of $0.01 par value each and
2,994,000 "B" Preferred Shares of $0.0016 (the 6 recurring) par value each to
US$91,650.00 divided into 40,000,000 Common Shares of $0.0016 (the 6 recurring)
par value each, 1,000,000 "A" Preferred Shares of $0.01 par value each and
8,994,000 "B" Preferred Shares of $0.0016 (the recurring) par value each.
2. That the Articles of Association of the Company be amended by the deletion of
the first paragraph of Article 2(a) in its entirety and the substitution
therefor of the following new first paragraph of Article 2(a):
SHARE CAPITAL
2 (a) The Capital of the Company is $91,650.00 in the currency of the United
States of America divided into 1,000,000 "A" Preferred Shares of $0.01 par value
each, 8.994,000 "B" Preferred Shares of $0.0016 (the 6 recurring) par value each
and 40,000,000 Common Shares of $0.0016 (the 6 recurring) par value each and
such A Preferred Shares shall confer upon their holders the following rights,
that is:
Dated the 27th, day of February A.D., 1996.
POLYDEX PHARMACEUTICALS LIMITED
By: Sarah M. Lobosky
Assistant Secretary
-1-
<PAGE>
CERTIFIED COPY OF CORPORATE RESOLUTION
OF
POLYDEX PHARMACEUTICALS LIMITED
Registration No.: 24,178
I, Sarah M. Lobosky, Assistant Secretary of Polydex Pharmaceuticals Limited, DO
HEREBY CERTIFY that the following is a true and correct copy of a resolution
passed by a majority vote of the Shareholders of Polydex Pharmaceuticals Limited
(the "Company") at a meeting held on Twentieth day of July, A.D., 1994:
RESOLVED THAT the Articles of Association of the Company be amended in the
following respects:
1 (a) That the following words be inserted at the end of Article 54 which shall
continue:
"...and may determine in what rotation such increased or reduced number is to go
out of office."
(b) That Article 66 be re-designed as Article 66A.
(c) That the following new Articles 66B and 66C be inserted after Article 66A:
66B. At the Annual General Meeting to be held in 1994, the Members shall appoint
up to one-third of the complement of the Board for one year term, up to
one-third of the complement of the Board for a two year term and up to one-third
of the complement of the Board for a three year term to the intent that there
shall be rotation of the Directors on a three year cycle. Consequently, at the
Annual General Meeting to be held in 1995, the Directors appointed in 1994 for
one year shall retire and they or their successors shall be reappointed or
appointed and the case may be for a three year term; at the annual General
Meeting to be held in 1996 the Directors appointed in 1994 for a two year term
shall retire and they or their successors shall be reappointed or appointed as
the case may be for a three year term; and at the Annual General Meeting to be
held in 1997 and in each subsequent year the Director (or Directors, up to
one-third of the complement of the Board) who have been longest in office (being
those then completing their three year term) shall retire.
66C. Notwithstanding the provisions of Article 66A, a retiring Director shall
-2-
<PAGE>
hold office until the dissolution or adjournment of the meeting at which his
successor is elected.
(d) That the following words be inserted at the end of Article 68 which shall
continue:
"........and so that where an appointment is made to a casual vacancy the term
of the appointment shall not exceed the term for which the predecessor would
have held office if he had continued for his full term."
2. That any one director or officer of the Company be and he is hereby
authorized and directed to execute and deliver, for and on behalf of the
Company, all documents and to do all things necessary or desirable to effect the
amendment to the Articles of Association of the Company as described herein,
including the execution and delivery of Articles of Amendment in prescribed form
to the appropriate regulatory authorities in The Bahamas, and otherwise to
effect the implementation of this resolution.
Given under the Common Seal of the
Company of this 26 day of
August 1994;
/s/ Sarah Lobosky
Assistant Secretary
-3-
<PAGE>
CERTIFIED COPY OF CORPORATE RESOLUTION
OF
POLYDEX PHARMACEUTICALS LIMITED
Registration No.: 24,178
I, Sarah M. Lobosky, Assistant Secretary of Polydex Pharmaceuticals Limited, DO
HEREBY CERTIFY that the following is true and correct of resolutions passed by a
majority vote of the Shareholders of Polydex Pharmaceuticals Limited (the
"Company") at a meeting held on the Thirteenth day of October, A.D. 1993:
RESOLVED:
1. That the capital of the Company be increased from US$64,990.00 divided into
30,000,000 Ordinary shares of $0.0016 each (the 6 recurring), 1,000,000 A
preferred shares of $0.001 each and 2,994,000 B preferred shares of $0.0016 each
(the 6 recurring) to US$81,650.00 divided into 40,000,000 Ordinary shares of
$0.0016 each (the 6 recurring), 1,000,000 A preferred shares of $0.01 each and
2,994,000 B preferred shares of $0.0016 each (the 6 recurring).
2. That the Articles of Association of the Company be amended by the deletion of
the first paragraph or Article 2(a) in its entirety and the substitution
therefor of the following new first paragraph of Article 2(a):
SHARE CAPITAL
2(a) The Capital of the Company is $81,650.00 in the currency of the United
States of America divided into 1,000,000 A Preferred Shares of $0.01 each,
2,994,000 B Preferred Shares of $0.0016 (the 6 recurring) each and 40,000,000
Ordinary Shares of $0.0016 (the 6 recurring) each and such A Preferred Shares
shall confer upon their holders the following rights, that is:
Dated the Seventh day of December, A.D., 1993.
POLYDEX PHARMACEUTICALS LIMITED
By: Sarah M. Lobosky,
Assistant Secretary
-1-
<PAGE>
CERTIFIED COPY OF CORPORATE RESOLUTION
OF
POLYDEX PHARMACEUTICALS LIMITED
Frank J. Cooney, Secretary of Polydex Pharmaceuticals Limited, does hereby
certify that the following is a true and correct copy of a resolution passed by
a majority vote of the Shareholders of Polydex Pharmaceuticals Limited (the
"Corporation") at a meeting held on August 20, 1990:
BE IT RESOLVED THAT the capital of the Company be increased from US $49,990.00
divided into 21,000,000 Ordinary shares of $0.0016 each (the 6 recurring),
1,000,000 A preferred shares of $0.01 each and 2,994,000 B preferred shares of
$0.0016 each (the 6 recurring) to US $64,990.00 divided into 30,000,000 Ordinary
shares of $0.0016 each (the 6 recurring), 1,000,000 A preferred shares of $0.01
each and 2,994,000 B preferred shares of $0.0016 each (the 6 recurring).
POLYDEX PHARMACEUTICALS LIMITED
By, Frank J. Cooney, Secretary
(Corporate Seal)
Boynton Beach, Florida
July 22, 1991
-1-
<PAGE>
THE COMPANIES ACT
COMPANY LIMITED BY GUARANTEE AND
HAVING A CAPITAL DIVIDED INTO SHARES
SPECIAL RESOLUTIONS
OF
POLYDEX PHARMACEUTICALS LIMITED
At the Annual General Meeting of the Members of the Company duly convened and
held at the offices of the Company, Second Floor, 284 Bay Street, Nassau,
Bahamas on the 14th day of September, 1987 the following Resolution was duly
passed as a Special Resolution:-
RESOLUTION
The Special Resolution attached hereto
as Schedule A was passed,
At an Extraordinary General Meeting of the Members of the Company duly convened
and held at the same place on the 30th day of September, 1987 the following
Resolution was duly passed as an Ordinary Resolution:-
RESOLUTION
The Special Resolution attached hereto
as Schedule A, previously passed, was
confirmed.
Dated the 30th day of September, A.D. 1987.
Secretary
-1-
<PAGE>
SCHEDULE A
Special Resolution Reclassifying the Capital of the Company into Ordinary
(Common) and Preferred Shares.
RESOLVED:
1. That the authorized capital of the Company of US$49,990.00 presently divided
into 29,994,000 shares of $0.0016 (the 6 recurring) be restructured to comprise
more than one class,
2. That the shares in the capital of the Company which are presently issued and
outstanding being 14,294,603 in number be classified as Ordinary shares.
3. That the shares in the capital of the Company which are presently unissued
being 15,699,397 in number be classified as follows: -
(1) 6,705,397 shares thereof as Ordinary Shares;
(2) 6,000,000 shares thereof as A Preferred Shares; and
(3) 2,994,000 shares thereof as B Preferred Shares.
4. That pursuant to the provisions of Article 18 (b) of the Articles of
Association of the Company the said 6,000,000 shares of par value $0.0016 (the 6
recurring) each presently unissued, now classified as A Preferred Shares, be
consolidated such that for every 6 shares thereof 1 share of par value $0.01 be
obtained,
5. That the Articles of Association of the Company be amended by the deletion of
Article 2 in its entirety and the substitution therefor of the following new
Article.
SHARE CAPITAL
2 (a) The capital of the Company is $49,990.00 in the Currency of the United
States of America divided into 1,000,000 A Preferred Shares of $0.01 each,
2,994,000 B Preferred Shares of $0.0016 (the 6 recurring) each and 21,000,000
Ordinary Shares of $0.0016 (the 6 recurring) each and such A Preferred Shares
shall confer upon their holders the following rights, that is;
-2-
<PAGE>
1. the right out of the profits of the Company resolved under the Articles of
Association to be distributed to a fixed cumulative preferential dividend at the
percentage rate per annum on the capital for the time being paid up thereon as
shall be determined by resolution of the Board of Directors prior to the issue
thereof;
2. the right of ranking in a winding up as regards return of capital and payment
of arrears of dividend down to the commencement of the winding up (whether
earned or declared or not) in priority to the Ordinary Shares but shall not
confer the right to any further participation in profits or assets; and
3. the right, upon terms and conditions to be fixed by the Company's Board of
Directors, to convert all or part of their A Preferred Shares into Ordinary
Shares of the Company.
And the holder thereof shall be subject to the following, that is
(i) the right of the Company to require the holder to convert part or the whole
of A Preferred Shares held by him into Ordinary Shares in accordance with the
provisions of the next following paragraph (b) of this Article; and
(ii) the right of the Company to redeem part or the whole of the A Preferred
Shares held by him on the terms set out in the next following paragraph (c) of
this Article.
(b) The Company shall be entitled from time to time and at any time prior to the
commencement of the winding-up of the Company to convert part or the whole of
the A Preferred Shares into Ordinary Shares by notice to the holders thereof
stating that it thereby converts the number of shares specified in the said
notice. The notice shall take effect ten (10) days after same being sent
certified mail, return receipt requested, postage prepaid to all holders thereof
and thereupon the A Preferred Shares comprised in the notice shall be
automatically converted into and thenceforth be called and known as Ordinary
Shares which will rank pad passu in all respects with the remaining Ordinary
Shares. All rights to the accruing preference dividend on such shares shall be
extinguished and the shares shall participate in full in all dividends declared
on the Ordinary Shares thereafter except in respect of the financial year
immediately preceding the financial year in which the conversion was effected
and on the footing that the shares had at all times from and including the
commencement of the financial year in which the same were converted Into
Ordinary Shares. Forthwith upon any such conversion the Company shall issue to
the holder a new certificate for the Shares so converted as Ordinary Shares
-3-
<PAGE>
comprised in the the Certificates required by the notice to be deposited at the
office of the Company.
(c) The Company shall be entitled from time to time and at any time prior to the
commencement of the winding up of the Company to redeem part or the whole of the
A Preferred Shares by notice the holders thereof and on such terms as shall be
determined by resolution of the Board of Directors prior to the issue thereof.
(d) Upon any increase of capital the Company is at liberty to issue any new
shares with any preferential deferred qualified or special rights, privileges or
conditions attached thereto.
(e) the whole of the unissued Shares of the Company for the time being shall be
under the control of the Directors who may allot or otherwise dispose of the
same to such persons on such terms and conditions and at such times as the
Directors think fit and by resolution prior to their issue shall determine
provided that no share shall be issued until it is fully paid.
6. That any one director or officer of the Company be and he is hereby
authorized and directed to execute and deliver, for and on behalf of the
Company, all documents and to do all things necessary or desirable to effect the
amendment to the Articles of Association of the Company as described herein,
including the execution and delivery of Articles of Association in prescribed
form to the appropriate regulatory authorities in the Bahamas, and otherwise to
effect the implementation of this resolution.
-4-
<PAGE>
The Companies Act
COMPANY LIMITED BY GUARANTEE AND HAVING A
CAPITAL DIVIDEND INTO SHARES
ARTICLES OF ASSOCIATION
of
POLYDEX CHEMICALS LIMITED
1. In the interpretation of these presents, unless there be something in the
subject or context inconsistent therewith:
"The Act: or "the Statute" means The Companies Act of The Bahamas as amended
from time to time;
"Special Resolution: and "Extraordinary Resolution" have the meanings assigned
thereto respectively by the Act;
"the Directors" means the Directors for the time being;
"the Office" means the registered office for the time being of the Company;
"the Register" means the register of members to be kept pursuant to The
Companies Act;
"month" means calendar month;
" in writing" and "written" include printing, lithography and other modes of
representing or reproducing words in a visible form. Words importing the
singular number only include the plural number and vice versa;
"Secretary" shall include any person appointed by the Directors to perform any
of the duties of the Secretary, and where any person is appointed to act as an
Assistant Secretary, shall include such person;
"member" and "shareholder" means a registered holder for the time being of an
issued share of the Company and any person, firm or corporation who presents a
transfer of shares to the Company for registration or on whose behalf such a
transfer is so presented shall be deemed to have agreed to become a member of
the Company;
"Treasurer" shall mean any person appointed by the Directors to perform any of
the duties of the Treasurer, and where any person is appointed to act as an
-1-
<PAGE>
Assistant Treasurer, shall include such person. Words importing persons include
corporations.
SHARE CAPITAL
2. (a) the capital of the Company is fifty thousand dollars ($50,000.00) in the
currency of the United States of America divided into five million (5,000,000)
shares of a par value of one dollar ($0.01) each, with power to divide the
shares in the capital for for the time being into several classes, and to attach
thereto respectively any preferential, deferred, qualified or special rights,
privileges or conditions, whether as to voting or otherwise;
and
(b) the whole of the unissued shares of the Company for the time being shall
consist of one class of shares and shall be under the control of the Directors
who may allot or otherwise dispose of the same to such persons on such terms and
conditions and at such times as the Directors think fit provided that no share
shall be issued until it is fully paid.
SHAREHOLDERS
3. Save as herein otherwise provided, the Company shall be entitled to treat the
registered holder of any share as the absolute owner thereof and accordingly
shall not, except as ordered by a Court of competent jurisdiction or as by the
Act required, be bound to recognize any equitable or other claim to or interest
in such share on the part of any other person and the Company shall not be bound
to see the execution of any trust whether express or implied or constructive in
respect of any share.
4. If several persons are registered as joint holders of any shares the first
named upon the Register shall, as regards service of notices, be deemed the sole
owner thereof. Any of such persons may give effectual receipt for dividends.
5. For the purposes of the quorum, joint holders of any voting shares shall be
considered as one number.
SHARE CERTIFICATES
6. Every registered holder of any share shall be entitled without payment to
receive within two months after allotment or registration of transfer one
certificate for all shares of any one class held by such person, or several
certificates each for one or more of his shares of any one class. Where a member
transfers part only of the shares comprised in the certificate shall be
-2-
<PAGE>
cancelled and a new certificate for the balance of such shares issued in lieu
thereof without charge.
7. Share certificates (and the form of share transfer thereon) shall be in such
form as the Directors may from time to time approve and may be printed or
reproduced on the reverse side of the share certificates for the Class A
preference shares of Polydex Chemicals (Canada) Limited. Every certificate shall
be issued under the seal of the Company which may be a facsimile and shall be
signed by the Chairman of the Board (if any), the Vice-Chairman (if any), the
President or a Vice-President and the Secretary or an Assistant Secretary (if
any) holding office at the time of signing and notwithstanding any change in the
persons holding such offices between the time of actual signing and the issuance
of any certificate and notwithstanding that the Chairman of the Board, the
Vice-Chairman, the President or Vice-President or Secretary or
Assistant-Secretary signing may not have held office at the date of the issuance
of such certificate, any such certificate so signed and sealed shall be valid
and binding upon the Company. Every certificate shall specify the number of
shares to which it relates and shall state that such shares are fully paid. The
Company shall not be bound to register more than three persons as the joint
holders of any shares (except in the case of executors or trustees or a deceased
member) and the Company shall not be bound to issue more than one certificate
for a share held jointly by several persons and delivery of a certificate to one
joint holder shall be sufficient delivery to all.
8. Notwithstanding the provisions of clause 7 hereof, the signature of the
Chairman of the Board, the Vice-Chairman, the President or Vice-President may be
printed, engraved, lithographed or otherwise mechanically reproduced upon
certificates for shares in the capital of the Company and certificates so signed
shall be deemed to have been manually signed by the Chairman of the Board, the
Vice-Chairman, the President or Vice-President whose signature is so printed,
engraved, lithographed or otherwise mechanically reproduced thereon and shall be
as valid to all intents and purposes as if they had been signed manually. Where
the Company has appointed a transfer agent, the signature of the Secretary or
Assistant-Secretary may also be printed, engraved, lithographed or otherwise
mechanically reproduced and when countersigned by or on behalf of a transfer
agent or branch transfer agent, share certificates so signed shall be as valid
to all intents and purposes as if they had been signed manually.
9. In case of the defacement, destruction, theft or loss of a certificate for
shares held by any shareholder, the fact of such defacement, destruction, theft
or loss shall be reported to the Company or to a transfer agent or branch
transfer agent of the Company, if any, with a statement verified by oath or
statutory declaration as to the defacement, destruction, theft or loss and the
-3-
<PAGE>
circumstances concerning the same and with the request for the issuance of a new
certificate to replace the one so defaced, destroyed, stolen or lost. Upon
giving to the Company, (or if there be a transfer agent and/or branch transfer
agent or agent and/or registrar and/or branch registrar or registrars,
hereinafter in this paragraph collectively referred to as the "Company's
transfer agents and registrars", then to the Company and the Company's transfer
agents and registrars) of a bond of a surety company or other security approved
by the Directors and in such form as is approved by the Directors or by the
Secretary or the Treasurer of the Company indemnifying the Company and the
Company's transfer agents and registrars, if any, against all loss, damage or
expense to which the Company and/or the Company's transfer agents and
registrars, may be put or be liable to by reason of the issuance of a new
certificate to such shareholder, a new certificate may be issued in replacement
of the one defaced, destroyed, stolen or lost if such issuance is order and
authorized by the Chairman of the Board of Directors (if any) or the President
or the Secretary or the Treasurer of the Company or by resolution of the
Directors.
10. All transfers of shares may be effected by transfer in such form as the
Directors may approve.
11. The instrument of transfer of a share shall be executed by the transferor or
by the transferor's attorney duly authorized and, if required by the Directors,
the transferee, and the transferor shall be deemed to remain the holder of the
share until the name of the transferee is entered in the Register in respect
thereof.
12. The Directors shall refuse to permit the registration of a transfer of fully
paid shares into the name of a transferee where the necessary Exchange Control
approval has not been obtained. The Directors may also refuse to permit the
registration of a transfer of fully paid shares registered in the name of a
member who is indebted to the Company provided that such shares are not at such
time listed on a stock exchange located any where in North America and
recognized by the law of the country of location.
b) The transfer of shares of the Company shall be restricted in that until
Polydex Chemicals (Canada) Limited, a corporation continued under the Canada
Business Corporations Act by articles of continuance redeems or purchases for
cancellation all the issued and outstanding 8% non-cumulative, redeemable
non-voting Class A preference shares without nominal or par value in the capital
stock of the said corporation, no transfer or other disposition of any common
share of a par value of U.S. $.01 the Company shall be effective unless a
simultaneous transfer or disposition is made by the same transferor's to the
-4-
<PAGE>
same transferee of an equal number of Class A preference shares of Polydex
Chemicals (Canada) Limited.
13. The Directors may decline to recognize any instrument of transfer, unless
the instrument of transfer is deposited at the Office or if there be a transfer
agent and/or a branch transfer agent or agents and/or registrar and/or branch
registrar or registrars at any of the offices thereof or at such other place or
places as the Directors may appoint, accompanied by the certificate for the
shares to which the instrument of transfer relates and such other evidence as
the Directors may reasonably require to show the right of the transferor's to
make the transfer and, if the instrument of transfer is executed by an attorney
on the transferor's behalf, the authority of the attorney so to do. All
instruments of transfer may be retained by the Company following registration.
14. The Directors may by resolution close the Register and the branch register
or registers, if any, for a period of time not exceeding forty-eight hours,
exclusive of Saturdays and holidays, immediately preceding any meeting of the
members.
TRANSMISSION OF SHARES
15. In case of the death of a shareholder, the survivors or survivor where the
deceased was a joint holder, and the executors or administrators of the estate
of the deceased where he was a sole or only surviving holder, shall be the only
person recognized by the Company as having any title to his interest in the
shares.
16. Any person becoming entitled to a share in consequence of the death or
bankruptcy of a member (upon supplying to the Company such evidence as the
Directors may reasonably require to show his title to the share) may, subject as
hereinafter provided, either be registered himself as holder of the share upon
giving notice to the Company of his desire to be so registered, or transfer such
share to some other person. All the limitations, restrictions and provisions
contained herein relating to the right to transfer and the registration of
transfers of shares shall be applicable to any such notice or transfer as
aforesaid as if the death or bankruptcy of the member had not occurred and the
notice or transfer were a transfer executed by such member.
17. Save as otherwise provided herein, a person becoming entitled to a share in
consequence of the death or bankruptcy of a member (upon supplying to the
Company such evidence as the Directors may reasonably require to show his title
to the share) shall be entitled to the same dividends and other advantages to
which he would be entitled if he were the registered holder of the share except
-5-
<PAGE>
that he shall not be entitled in respect thereof to exercise any right conferred
by membership in relation to meeting of the Company until he shall have been
registered as a member in respect of the share.
ALTERATION OF CAPITAL
18. The members may by Ordinary Resolution:
a) increase the authorized capital of the Company by the creation of new shares
of such amount as may be deemed expedient; all new shares shall be subject to
the provisions contained herein with reference to allotment, lien, transfer,
transmission and otherwise;
b) consolidate and divide all or any of the share capital into shares of larger
amount than its existing share;
c) convert all or any of the paid-up shares into stock and re-convert that stock
into paid-up shares of any denomination;
d) subdivide the shares or any of them into shares of smaller amount than is
fixed by these Articles of Association, so however that in the subdivision the
proportion between the amount paid and the amount (if any) unpaid on each
reduced share shall be the same as it was in the case of the share from which
the reduced share is derived; or
e) cancel any shares belonging to the company (including shares which at the
date of the passing of the resolution in that behalf have not been taken or
agreed to be taken by any person) and diminish the amount of its share capital
by the amount of the shares so cancelled;
f) reduce the shares or the share capital of the Company.
19. When authorized by the Directors, the Company may:
a) accept from any shareholder a donation of his shares without any
repayment of capital in respect thereof;
and
b) notwithstanding subclause 18 (f), purchase or otherwise acquire shares
issued by it, provided that the Company shall not make any payment to or
otherwise acquire shares issued by it if there are reasonable grounds for
believing that:
(i) the company is, or would after the payment be, unable to pay its
liabilities as they become due; or
(ii) the realizable value of the Company's assets would after the
payment be less than the aggregate of its liabilities and paid-up capital of all
classes.
c) Notwithstanding subclause 18(f) and subclause 19(b) the Company may
purchase or otherwise acquire shares issued by it to
(i) settle or compromise a debt or claim asserted by or against the
Company;
-6-
<PAGE>
(ii) eliminate fractional shares; or
(iii) fulfill the terms of a non-assignable agreement under which the
corporation has a option or is obliged to purchase shares owned be a director,
an officer or an employee of the Company provided that the Company shall not
make any payment to purchase or acquire under this subclause shares issued by it
if there are reasonable grounds for believing that
(iv) the Company is, or would after the payment, be unable to pay its
liabilities as they become due; or
(v) the realizable value of the Company's assets would, after the
payment, be less than the aggregate of its liabilities and the amounts required
for payment on a redemption or in a liquidation of all shares the holders of
which have a right to be paid prior to the holders of the shares to be purchased
or acquired. Where the Company accepts from any shareholder a donation of his
shares without any repayment of capital in respect thereof or purchases or
otherwise acquires any of the Company's shares in accordance with subclauses 19
(b) or 19 (c) above, the Directors may:
(i) cancel the shares at such time as they determine, in which case the
authorized and issued capital of the Company are thereby decreased and these
Articles of Association are amended accordingly; or
(ii) resell the shares at such time and price and on such terms as they
determine.
20. The Directors may from time to time at their discretion, raise or borrow or
secure the payment of any sum or sums of money on the credit of the Company for
the purposes of the Company.
21. The Directors may raise or secure the payment or repayment of such money in
such manner and upon such terms and conditions in all respects as they think fit
and in particular by the issue of bonds, mortgages, debentures or debenture
stock perpetual of otherwise, notes or other obligations of the Company charged
upon all or any part of the property of the Company (both present and future).
22. Debentures, debenture stock and other securities may be made assignable,
free from any equities, between the Company and the person to whom the same may
be issued.
23. The Directors may from time to time authorize one or more directors,
officers or employees of the company or other persons, whether connected with
the the Company or not, to sign, execute and give on behalf of the Company all
documents, agreements and promises necessary or desirable for the purposes set
out in sections 20, 21 and 22 and to draw, make, accept, endorse, execute and
issue cheques, promissory notes, bills of exchange, bills of lading and other
negotiable or transferable instruments and the same and all renewals thereof or
-7-
<PAGE>
substitution therefor so signed shall be binding upon the Company.
GENERAL MEETINGS OF MEMBERS
24. The first annual general meeting of members shall be held at such time (not
being more than twelve months) after the registration of the Company as the
subscribers to the Memorandum of Association may determine in the City of Nassau
in the Island of New Providence or at such other place as may be prescribed by
the subscribers to the Company's Memorandum of Association.
25. Subsequent annual general meetings of the members shall be held in each and
every year at such time (within a period of not more than eighteen months after
the holding of the last preceding annual general meeting) at the Office of the
Company or at such other place as may be prescribed by the Directors.
26. All other general meetings of the members of the Company are sometimes
herein referred to as extraordinary general meetings.
27. The Directors may whenever they think fit, and shall on requisition in
accordance with the provisions of the next succeeding paragraph hereof, proceed
to convene an extraordinary general meeting.
28. The holders of not less than 5% of the issued shares of the Company that
carry the right to vote at a meeting sought to be held may in writing signed by
the addressed to the Secretary and sent by registered post to or left at the
Office requisition an extraordinary general meeting of the Company and shall
specify a resolution or resolutions to be proposed at such extraordinary general
meeting as a special resolution or otherwise and may require that a memorandum
not exceeding 200 words in length and approved by the requisitions be prepared
at the Company's expense and enclosed with each notice of extraordinary general
meeting so convened. Upon receipt of the requisition, the Directors shall
forthwith call an extraordinary general meeting of the members for the
transaction of the business stated in the requisition. If the Directors do no
within twenty-one days from the date of the receipt of the requisition call and
hold such meeting, any of the requisitionists may call such meeting which shall
be held within sixty days from the date of the deposit of the requisition. Any
reasonable expenses incurred by the requisitionists by reason of the failure of
the Directors to call such meeting shall be paid to the requisitions by the
Company.
29. Twenty-one days' notice at the least (exclusive of the day on which it is
given and inclusive of the day for which it is given) of all general meetings of
-8-
<PAGE>
members specifying the place, the day and the hour of meeting and in case of
special business the general nature of such business shall be given to the
members in manner hereinafter mentioned or in such manner, if any, as may be
prescribed by the members in general meeting; but the non-receipt of such notice
by any member shall not invalidate the proceedings at any meeting.
30. (a) Every notice calling a general meeting shall specify the place and the
day and the hour of the meeting and other shall appear with reasonable
prominence in every such notice a statement that a member entitled to attend and
vote is entitled to appoint a proxy to attend and vote instead of him and that a
proxy need not be a member of the Company.
(b) In the case of an annual general meeting, the notice shall also specify the
meeting as such.
(c) In the case of any annual general meeting at which business other than
routine business is to be transacted, the notice shall specify the general
nature of such business and in the case of any extraordinary general meeting the
notice shall specify the general nature of all of the business to be transacted;
and in each case, if any resolution is to be proposed as a Special Resolution,
the notice shall contain a statement to the effect.
(d) General meetings of members may be held without previous notice if all
members entitled to be present are present in person or by proxy or waive notice
of such meeting in writing. Any member may waive notice of a general meeting by
an instrument in writing signed by him or by telegram, cable or telex before, at
or after such meeting.
31. Routine business shall mean and include only business transacted at an
annual general meeting of the following general nature, that is to say:
(a) receiving and considering the financial statements and the report of the
auditors thereof;
(b) appointing the auditors and fixing the remuneration for the auditors or
determining the manner in which such remuneration is to be fixed;
(c) electing or appointing directors.
32. When all members entitled to be present and vote sign either personally or
by proxy the minutes of an annual general or an extraordinary general meeting,
the same shall be deemed to have been duly held notwithstanding that members
have not actually come together or that there may have been technical defects in
the proceedings and a resolution
-9-
<PAGE>
in writing signed by all the members aforesaid shall be as valid and effectual
as if it had been passed at a meeting of the members duly called and
constituted.
PROCEEDINGS AT GENERAL MEETINGS
33. No business shall be transacted at any general meeting of the members unless
a quorum is present. Except as otherwise required by law, a quorum for the
transaction of business shall be two persons present and holding or representing
by proxy not less than one share each.
34. The Chairman of the Board of Directors, failing whom the Vice-Chairman of
the Board of Directors, failing whom the President, failing whom a
Vice-President of the Company, shall preside as Chairman at a general meeting.
If there be no such Chairman of the Board, Vice-Chairman of the Board, President
or Vice-President present at any meeting within fifteen minutes after the time
appointed for holding the meeting who is willing to act, the Directors present
shall choose one of their number (or, if no Director be present or if all the
Directors present decline to take the chair, the members present shall choose
one their number) to be Chairman of the meeting.
35. The Chairman may, with the consent of the meeting, adjourn any meeting from
time to time and from place to place but no business be transacted at any
adjourned meeting other than the business left unfinished at the meeting from
which the adjournment took place.
36. When a meeting is adjourned for thirty days or more, notice of the adjourned
meeting shall be given as in the case of an original meeting. Save as aforesaid,
it shall not be necessary to give any notice of an adjournment or of the
business to be transacted at an adjourned meeting.
37. At any general meeting a resolution put to the vote of the meeting shall be
decided on a show of hands unless a poll is (before or on the declaration of the
result of the show of hands) demanded by either the Chairman of the meeting or
any member present in person or by proxy and entitled to vote. A demand for a
poll may be withdrawn. Unless a poll be so demanded (and the demand be not
withdrawn) a declaration by the Chairman of the meeting that a resolution has
been carried, or carried unanimously, or by a particular majority, or lost, and
an entry to that effect in the minute book, shall be conclusive evidence of the
fact without proof of the number or proportion of the votes recorded for or
against such resolution.
38. If a poll is duly demanded and the demand is not withdrawn, the poll shall
be taken in such manner as the Chairman of the meeting may direct, and the
-10-
<PAGE>
result of the poll shall be deemed to be the resolution of the meeting at which
the poll was demanded. The Chairman of the Meeting may (and if so directed by
the meeting shall) appoint scrutineers and may adjourn the meeting to some place
and time fixed by him for the purpose of declaring the result of the poll.
39. In the case of an equality of votes, whether on a show of hands or on a
poll, the Chairman of the Meeting at which the show of hands takes place or at
which the poll is demanded shall be entitled to a casting vote.
40. Upon a poll being demanded on any question, the same shall be taken
forthwith.
VOTES OF MEMBERS
41. Subject to any special rights or restrictions as to voting attached by or in
accordance with these Articles to any class of shares, on a show of hands every
member who is present in person shall have one vote and on a poll every member
who is present in person or by proxy shall have one vote for every share of
which he is the holders.
42. Where there are joint registered holders of any share, any one of such
persons may vote at any meeting of members, either personally or by proxy, in
respect of such share as if he were soley entitled thereto; and if more than one
of such joint holders be present at any such meeting personally or by proxy,
that one of the said persons so present whose name stands first on the register
in respect of such shares shall alone be entitled to vote in respect thereof.
Several executors or administrators of a deceased member in whose sole name any
shares stand shall for the purposes of this Article be deemed joint holders
thereof.
43. A member of unsound mind, or in respect of whom an order has been made by
any court having jurisdiction in lunacy, may vote, whether a show of hands or on
a poll by his committee, curator bonis or other person in the nature of a
committee or curator bonis appointed by such court, provided that such evidence
as the Directors may require of the authority of the person claiming to vote
shall have been deposited at the Office not less than forty-eight hours before
the time appointed for holding the meeting or adjourned meeting.
44. No objection shall be raised as to the admissibility of any vote except at
the meeting or adjourned meeting at which the vote objected to is or may be
given or tendered, and every vote not disallowed at such meeting shall be valid
for all purposes. Any such objection shall be referred to the Chairman of the
meeting whose decision shall be final and conclusive.
-11-
<PAGE>
45.On a poll votes may be given either personally or by proxy, and a person
entitled to more than one vote need not use all his votes or cast all the votes
he uses in the same way.
46. A proxy need not be a member of the Company.
47. Any instrument appointing a proxy shall be in the following form with such
variations (if any) as circumstances may require or the Directors may approve:-
"POLYDEX CHEMICALS LIMITED"
"I/We,
"of
"
"a member of the above-named Company, hereby
"appoint
"of
"as my/our proxy to act and vote for me/us on
"my/our behalf at the (Ordinary, Extraordinary or
"adjourned, as the case may be) Meeting of the
"Company to be held on the day of
"and at every adjournment thereof.
"As witness may hand this day of, 19 ."
48. A instrument appointing a proxy must be produced at the meeting or must be
left at the office or such other place, if any, as is specified for that purpose
in the notice convening the meeting.
49. An instrument appointing a proxy shall be deemed to include the right to
demand or join in demanding a poll and shall, unless the contrary is stated
thereon, be valid as well for any adjournment of the meeting as for the meeting
to which it relates.
50. A vote given in accordance with the terms of an instrument of proxy or of a
power of attorney shall not be valid if the appointor shall be present at the
meeting but shall be valid notwithstanding the previous death or incapacity of
the transfer of the share in the Company in respect of which the vote is given,
provided that no intimation in writing of the death, revocation or transfer
shall have been received at the office before the meeting.
51. Any corporation which is a member of the Company may by resolution of its
-12-
<PAGE>
Directors or other governing body authorize such person as it thinks fit to act
as its representative at any meeting of the Company or any class of members of
the Company, and the person so authorized shall be entitled to exercise the same
powers on behalf of such corporation as the corporation could exercise if it
were an individual member of the Company.
VARIATION OF RIGHTS
52. Whenever the capital of the Company is divided into different classes of
shares, the special rights attached to any class may, subject to the provisions
of the Act, be varied or abrogated, either with the consent in writing of the
holders of three-fourths of the issued shares of the class, or with the sanction
of an Extraordinary Resolution passed at a separate general meeting of such
holders (but not otherwise), and may be so varied or abrogated whilst the
Company is a going concern or in contemplation of a winding-up. To every such
separate general meeting all the provisions of these Articles relating to
general meetings of the Company, or to the proceedings thereat, shall apply
mutatis mutandis. The necessary quorum shall be two persons holding or
representing by proxy at least one share of the class outstanding each. If at
any such separate general meeting a quorum is not present within half an hour of
the time appointed the meeting shall stand adjourned until the same day in the
next week at the same time and place or to such other day, time and place as the
Directors may determine, and at such adjourned meeting of such holders a quorum
shall be two persons present holding or representing by proxy at least one share
of the class outstanding each. The special rights conferred upon the holders of
any shares or class of shares shall not, unless otherwise expressly provided by
the terms of issue, be deemed to be modified by the creation or issue of further
shares ranking pari passu therewith.
DIRECTORS
53. Subject as hereinafter provided the Directors shall not be less than three
nor more than six in number. The first Directors shall be appointed at the first
general meeting of the members and their number shall be within the limits
above-mentioned. The Company may by ordinary resolution from time to time
increase or reduce the maximum or minimum number of Directors.
54. The ordinary remuneration of the Directors shall from time to time be
determined by the Directors.
55. The Directors may repay to any Director all such reasonable expenses as he
may incur in attending and returning from meetings of the Directors, or of any
committee of the Directors, or general meetings, or otherwise in or about the
-13-
<PAGE>
business of the Company.
56. Any Director who is appointed to any office or to any executive office
including the office of President or Vice-President or who serves on any
committee or who otherwise performs services which in the opinion of the
Directors are outside the scope of the ordinary duties of a Director, may be
paid such extra remuneration by way of salary or otherwise as the Directors may
determine.
57. The Directors shall have power and be deemed always to have had power to pay
and agree to pay pensions or other retirement, superannuation, death or
disability benefits to or to any person in respect of any Director or
ex-Director who may hold or have held any executive office or any office of
profit under the Company and for the purpose of providing any such pensions or
other benefits to contribute to any scheme or fund or to pay premiums.
58. A Director of the Company who is in any way directly or indirectly
interested in a contract or transaction or a proposed contract or transaction
with the Company shall disclose the nature and extent of his interest at a
meeting of the Directors of the Company. In the case of a proposed contract or
transaction, the declaration shall be made at the meeting of the Directors at
which the question of entering into the contract or transaction is first taken
into consideration or, if the Director is not at the date of that meeting
interested in the proposed contract or transaction, at the next meeting of the
Directors held after he becomes so interested. In a case where the Director
becomes interested in a contract or transaction after it is made, the
declaration should be made a the first meeting of the Directors held after he
becomes so interested. A general notice given to the Directors of the Company by
a director to the effect that he is a shareholder or member of or otherwise
interested in any other company or is a member of a specified firm and is to be
regarded as interested in any contract or transaction made with such other
company or firm, shall be deemed to be a sufficient declaration of interest in
relation to a contract or transaction so made, but no such notice is effective
unless it is given at a meeting of the Directors, or the Director takes
reasonable steps to make sure that it is brought up at the next meeting of the
Directors after it is given. If a director has made a declaration of his
interest in a contract or transaction or proposed contract or transaction in
compliance with this paragraph and has not voted in respect thereof, and if he
is acting honestly and in good faith, he is not accountable to the Company or to
any of its members or creditors for any profit realized from the contract or
transaction, and the contract or transaction, if it is in the best interest of
the Company, is not voidable only by reason of holding that office or of the
fiduciary relationship established thereby. Notwithstanding anything in this
paragraph, a director is not
-14-
<PAGE>
accountable to the Company or to any of its members or creditors for any profit
realized from such contract or transaction and the contract or transaction if it
is in the best interests of the Company, is not by reason only of his interest
therein voidable, if it is confirmed by an Ordinary Resolution of the members
duly called for that purpose and if his interest in the contract or transaction
is declared in reasonable detail in the notice calling the meeting.
OFFICERS AND EXECUTIVE DIRECTORS
59. The officers of the Company shall consist of a President and Secretary (or
one or more Assistant Secretaries) and may also comprise a Chairman of the
Board, a Vice-Chairman of the Board, one or more Vice-Presidents, a Treasurer
(or one or more Assistant Treasurers) or any combination of the aforesaid
offices and such other officers as the Directors may determine. The officers
shall be appointed by the Directors and shall hold office at the will of the
Directors who may remove an officer at any time. The Directors shall have power
from time to time to appoint an officer or officers to fill an office becoming
vacant or to appoint an additional officer to a new office.
60. None of the officers (except the Chairman of the Board who must be a
Director) need be a member or Director.
61. Any person may hold more than one such office.
62. (a) The officers shall perform such duties as may from time to time be
prescribed by the Directors.
(b) The Chairman of the Board, whom failing the Vice-Chairman of the Board, whom
failing the President, shall be the chief executive officer of the Company,
responsible for carrying out the policy decisions made by the Directors. He
shall not originate policy and his powers of executing decisions of the Board
shall be collateral with and not to the exclusion of the powers of the
Directors.
(c) The Secretary shall convene meetings of the members and Directors and shall
attend the meetings and keep minutes thereof. He shall keep the corporate
records.
63. (a) The Director may from time to time appoint one or more of their body to
be holder of any executive office, including the office of Managing or Joint
Managing Director, on such terms and for such period as they may determine.
(b) The appointment of any Director to the office of Managing or Joint Managing
-15-
<PAGE>
Director shall be subject to termination if he ceases from any cause to be a
Director, but without prejudice to any claim he may have for damages for breach
of any contract of service between him and the Company.
64. The Directors may entrust to and confer upon the Managing Director any of
the powers exercisable by them as Directors upon such terms and conditions and
with such restrictions as they think fit, and either collaterally with or to the
exclusion of their own powers, and may from time to time revoke, withdraw, alter
or vary all or any of such powers.
APPOINTMENT AND RETIREMENT OF DIRECTORS
65. The office of a Director shall be vacated in any of the following events,
namely:
(a) If he becomes prohibited by law from acting as a Director.
(b) If he resigns by writing under his hand left at the Office.
(c) If he becomes bankrupt or has an adjudication order made against him or
compounds with his creditors generally.
(d) If he becomes of unsound mind.
66. The members in annual general meeting shall elect directors to serve on the
board of directors until their successors are elected and qualified or until
their earlier removal or retirement.
67. The Company may by Ordinary Resolution remove any Director before the
expiration of his period of office, notwithstanding any provision of these
Articles or any agreement between the Company and such Director, but without
prejudice to any claim he may have for damages for breach of any such agreement.
The Company may by a like resolution appoint another person in place of a
Director so removed from office. In default of such appointment the vacancy so
arising may be filled by the Directors as a casual vacancy.
68. The Directors shall have power at any time and from time to time to appoint
any person to be a Director either to fill a casual vacancy or as an additional
Director, but so that the total number of Directors shall not at any time exceed
the maximum number fixed by or in accordance with these Articles.
PROCEEDINGS OF DIRECTORS
-16-
<PAGE>
69. The Directors may meet together for the dispatch of business, adjourn and
otherwise regulate their meetings as they think fit. Meetings of the Directors
may be held anywhere in the world. Questions arising at any meeting shall be
determined by a majority of votes. In case of an equality of votes the Chairman
shall not have a second or casting vote. A Director may, and the Secretary on
the requisition of a Director shall, at any time summon a meeting of the
Directors. It shall be necessary to give two days' notice (exclusive of the day
on which it is served or deemed to be served and inclusive of the day for which
it is given) of a meeting of Directors to every Director but such notice may be
waived by any Director by an instrument in writing signed by him or by telegram,
cable or telex before, at or after such meeting.
70. The quorum necessary for the transaction of the business of the Directors
may be fixed by the Directors, and unless so fixed at any other number shall be
two. A meeting of the Directors at which a quorum is present shall be competent
to exercise all powers and discretions for the time being exercisable by the
Directors.
71. The continuing Directors may act notwithstanding any vacancies, but if and
so long as the number of Directors is reduced below the minimum number fixed by
or in accordance with these Articles the continuing Directors or Director may
act for the purpose of filling up such vacancies or a summoning general meetings
of the Company, but not for any other purpose. If there be no Directors or
Director able or willing to act, then any two members may summon a general
meeting for the purpose of appointing Directors.
72. The Directors may choose one of their number to be Chairman of the Board who
shall preside at their meetings. In the absence of the Chairman of the Board, if
any, the Vice-Chairman of the Board, if any (if he shall be a Director), or in
his absence, the President (if he shall be a Director) shall preside at meetings
of Directors provided always that nothing shall prevent the Vice-Chairman of the
Board or President from being chosen Chairman of the Board. If at any meeting
there is no Chairman of the Board or Vice-Chairman of the Board in existence, or
if neither the Chairman of the Board nor the Vice-Chairman of the Board nor the
President be present within fifteen minutes after the time appointed for the
holding the same, the Directors present may choose one of their number to be
Chairman of the meeting.
73. A resolution in writing signed by all the Directors shall be as effective as
a resolution passed at a meeting of the Directors duly convened and held, and
may consist of several documents in the like form, each signed by one more of
the Directors.
-17-
<PAGE>
74. All acts done by any meeting of Directors, or by any person acting as a
Director, shall as regards all persons dealing in good faith with the Company,
notwithstanding that there was some defect in the appointment or continuance in
office of any such Director, or person acting aforesaid, or that they or any of
them were disqualified or had vacated office, or were not entitled to vote, be
as valid as if every such person had been duly appointed and was qualified and
had continued to be a Director and had been entitled to vote.
BORROWING POWERS
75. The Directors may;
(a) borrow money on the credit of the Company;
(b) issue, sell or pledge debt obligations of the Company; or
(c) charge, mortgage, hypothecate or pledge all or any currently owned or
subsequently acquired real or personal, moveable or immovable property of the
Company, including book debts, rights, powers, franchises and undertaking, to
secure any debt obligations or any money borrowed, or other debt or liability of
the Company.
GENERAL POWERS OF DIRECTORS
76. The business of the Company shall be managed by the Directors, who may pay
all expenses incurred in forming and registering the Company, and may exercise
all such powers of the Company as are not by the Statute or by these Articles
required to be exercised by the Company in general meeting, subject nevertheless
to any regulations of these Articles, to the provisions of the Statue, and such
regulations, being not consistent with the aforesaid regulation or provisions,
as may be prescribed by Special Resolution of the Company, but no regulation so
made by the Company shall invalidate any prior act of the Directors which would
have been valid if such regulation had not been made. The general powers given
by this Article shall not be limited or restricted by any special authority or
power given to the Directors by any other Article.
77. The Directors may from time to time and at any time by power of attorney
under the seal appoint any company, firm or person or any fluctuating body of
persons, whether nominated directly or indirectly by the Directors, to be the
Attorney of Attorneys of the Company for such purposes and with such powers,
authorities and discretions (not exceeding those vested in or exercisable by the
Directors under these Articles) and for such period and subject to such
conditions as they may think fit, and any such power of attorney may contain
-18-
<PAGE>
such provisions for the protection and convenience of persons dealing with any
such Attorney as the Directors may think fit, and may also authorize any such
Attorney to subdelegate all or any of the powers, authorities and discretions
vested in him.
78. All cheques, promissory notes, drafts, bills of exchange, and other
negotiable or transferable instruments, and all receipts for moneys paid to the
Company, shall be signed, drawn, accepted, endorsed, or otherwise executed, as
the case may be, in such manner as the Directors shall from time to time by
resolution determine.
79. Contracts, documents or instruments in writing requiring the signature of
the Company may be signed by the Chairman of the Board, Vice-Chairman of the
Board, the President or a Vice-President or a Director and by the Secretary or
another Director and all contracts, documents or instruments in writing so
signed shall be binding upon the Company without further authorization or
formality. The Directors are authorized from time to time by resolution to
appoint any officer or officers or any other person or persons on behalf of the
Company either to sign contracts, documents or instruments in writing. The term
"contracts, documents or instruments in writing" as used in this Article shall
include deeds, mortgages, hypothecs, charges, conveyances, transfers and
assignments of property, real or personal, immovable or movable, agreements,
releases, receipts and discharges for the payment of money or other obligations,
conveyances, transfers and assignments of shares, warrants, bonds, debentures or
other securities and all paper writings.
In particular, without limiting the generality of the foregoing, the Chairman of
the Board, Vice-Chairman of the Board, the President or a Vice-President or a
Director together with the Secretary or another Director are authorized to sell,
assign, transfer, exchange, convert or convey all shares, bonds, debentures,
rights, warrants or other securities owned by or registered in the name of the
Company and to sign and execute (under the seal of the Company or otherwise) all
assignments, transfers, conveyances, powers of attorney and other instruments
that may be necessary for the purpose of selling, assigning, transferring,
exchanging, converting or conveying any such shares, bonds, debentures, rights,
warrants or other securities.
SEAL
80. The Directors shall provide for the safe custody of the seal, which shall
only be used by the authority of the Directors or of a committee of the
Directors authorized by the Directors in that behalf, and every instrument to
-19-
<PAGE>
which the seal shall be signed by the Chairman of the Board, Vice-Chairman of
the Board, President or a Vice-President or a Director and shall be
countersigned by the Secretary or another Director.
81. The Company may exercise the powers conferred by the Companies Seals Act
(Bahama Islands).
AUTHENTICATION OF DOCUMENTS
82. Any Director or the Secretary or any person appointed by the Directors for
the purpose shall have power to authentic ate any documents affecting the
constitution of the Company and any resolutions passed by the Company or the
Directors, and any books, records, documents and accounts relating to the
business of the Company, and to certify copies thereof or extracts therefrom as
true copies or extracts; and where any books, records, documents and accounts
are elsewhere than at the Office the local manager or other officers of the
Company having the custody thereof shall be deemed to be a person appointed by
the Directors as aforesaid.
83. A document purporting to be a copy of a resolution of the Directors or an
extract from the minutes of a meeting of the Directors which is certified as
such in accordance with the provisions of the last preceding Article shall be
conclusive evidence in favour of all persons dealing with the Company upon the
faith thereof that such resolution has been duly passed or, as the case may be,
that such extract is a true and accurate record of a duly constituted meeting of
the Directors. Where a resolution purports to have been signed by all of the
Directors or by all of the members, as the case may be, the signatures to such
resolution are admissible in evidence as prima facie proof of the signatures of
such Directors or members, as the case may be, that they purport to represent
and are admissible in evidence as a prima facie proof that the signatures to the
resolution were of all the Directors or all of the members entitled to vote at
meetings of the Directors or members, as the case may be, at the date that the
resolution purports to have been signed. Where minutes of all proceedings at a
meeting of Directors or shareholders purport to have been signed by the Chairman
of the meeting at which the proceedings where had or by the Chairman of the next
succeeding meeting, such minutes are admissible in evidence as prima facie proof
of the proceedings.
CUSTODY OF SECURITIES
84. All securities owned by the Company shall be lodged (in the name of the
-20-
<PAGE>
Company) with a bank or trust company or in a safety deposit box or, if so
authorized by a resolution of the Directors, with such other depositaries or in
such other manner as may be determined from time to time by the Directors. All
securities belonging to the Company may be issued and held in the name of a
nominee or nominees of the Company (and if issued or held in the names of more
than one nominee shall be held in the name of the nominees jointly with right to
survivorship) and shall be endorsed in blank with endorsement guaranteed in
order to enable transfer thereof to be completed and registration thereof to be
effected.
DIVIDENDS
85. The Directors may by resolution declare dividends either out of the capital
or the profits of the Company.
86. If and so far as in the opinion of the Directors the profits of the Company
justify such payments, the Directors may pay the fixed dividends on any class of
shares carrying a fixed dividend expressed to be payable on fixed dates on the
half-yearly or other dates prescribed for the payment thereof and may also from
time to time pay interim dividends of such amounts and on such dates as they
think fit.
87. Subject to the provisions of the Statute, where any asset, business or
property is bought by the Company as from a past date whether such date be
before or after the incorporation of the Company upon the terms that the Company
shall as from that date take the profits and bear and losses thereof, such
profits or losses may, at the discretion of the Directors, in whole or in part
be carried to revenue account and treated for all purposes as profits or losses
of the Company. Subject as aforesaid, if any shares or securities are purchased
cum dividend or interest, such dividend or interest may at the discretion of the
Directors be treated as revenue, and it shall not be obligatory to capitalize
the same or any part thereof.
88. No dividend or other moneys payable on or in respect of a share shall bear
interest as against the Company.
89. The Directors may retain the dividends payable upon shares in respect of
which any person is under the provisions as to transmission of shares
hereinbefore contained entitled to become a member, or which any person is under
those provisions entitled to transfer, until such person shall become a member
in respect of such shares or shall transfer the same.
90. The payment by the Directors of any unclaimed dividend or other moneys
-21-
<PAGE>
payable on or in respect of a share into a separate account shall not constitute
the Company a trustee in respect thereof and any dividend unclaimed after a
period of six years from the date of declaration of such dividend shall be
forfeited and shall revert to the Company.
91. The Directors may be resolution declare and pay a dividend in whole or in
part by the distribution of specific assets, and in particular of paid-up shares
or debentures of any other company or in any one or more such ways; and the
Directors may fix the value for distribution of such specific assets or any part
thereof and may determine that cash payments shall be made to any members upon
the footing of the value so fixed in order to adjust the rights of all parties
and may vest any such specific assets in trustees as may seem expedient to the
Directors.
92. Any dividend or other moneys payable in cash on or in respect of a share may
be paid by cheque or warrant sent through the post to the registered address of
the member or person entitled thereto, or, if two or more persons are registered
as joint holders of the share or are entitled thereto in consequence of the
death or bankruptcy of the holder, to any one such persons or to such person at
such address as such person or persons may by writing direct. Every such cheque
or warrant shall be made payable to the order of the person whom it is sent or
to such person as the holder or joint holders or person or persons entitled to
the share in consequence of the death or bankruptcy of the holder may direct and
payment of the cheque if purporting to be paid by the bank on which it is drawn
shall be a good discharge to the Company. Every such cheque or warrant shall be
sent at the risk of the person entitled to the money represented thereby.
93. If two or more persons are registered as joint holders of any share, or are
entitled jointly to a share in consequence of the death or bankruptcy of the
holder, any one of them any give effectual receipts for any dividend or other
moneys payable on or in respect of the share.
RESERVE
94. The Directors may from time to time set aside out of the profits of the
Company and carry to reserve such sums as they think proper which, at the
discretion of the Directors shall be applicable for any purpose to which the
profits of the Company may properly be applied, and pending such application may
either be employed in the business of the Company or be invested. The Directors
may divide the reserve into such special funds as they think fit, and may
consolidate into one fund any special funds or parts of any special funds into
which the reserve may have been divided. The Directors may also without placing
-22-
<PAGE>
the same to reserve carry forward any profits.
MINUTES AND BOOKS
95. The Directors shall cause minutes to be made and kept in books to be
provided for the purpose:
(a) of all appointments of officers made by the Directors;
(b) of the names of the Directors present at each meeting of Directors and of
any committee of Directors;
(c) of all resolutions and proceedings at all meetings of the Company and of any
class of members of the Company and of the Directors and of committees of
Directors.
96. The Directors shall duly comply with the provisions of the Statute and in
particular the provisions in regard to keeping a Register of Directors and
Managers, a Register of Members, and a Register of mortgages and charges, and in
regard to the production and furnishing of copies of such Registers and of any
Register of holders of debentures of the Company.
97. Any Register, index, minute book, book of account or other book required by
these Articles or the Statutes to be kept by or on behalf of the Company unless
required by the Statutes to be kept at the Office may be kept at such place or
places as the Directors may from time to time determine and may be kept either
by making entries in bound books or by recording them in any other manner. In
any case in which bound books are not used, the Directors shall take adequate
precautions for guarding against falsification and for facilitating it
discovery.
ACCOUNTS
98. (a) The Directors shall cause to be kept proper books of account in which
are set out all financial and other transactions of the Company including,
without limiting the generality of the foregoing, with respect to:
(i) all sums of money received and expended by the Company and the matters in
respect of which the receipt and expenditure takes place;
(ii) all sales and purchases by the Company;
(iii) the assets and liabilities of the Company;
-23-
<PAGE>
(iv) all other transactions affecting the financial position of the Company.
(b) For the purposes of the foregoing, proper books of accounts shall not be
deemed to be kept with respect to the matters aforesaid if there are not kept
such books as are necessary to give a true and fair view of state of the
Company's affairs and to explain its transactions.
99. The books of account shall be kept at the Office, or at such other place as
the Directors think fit, and shall always be open to the inspection of the
Directors. No member (other than a Director) shall have any right of inspecting
any account or book or document of the Company, except as conferred by statute
or authorized by the Directors.
100. The Directors shall at some date not later than eighteen months after the
incorporation of the Company and subsequently once at least in every year lay
before the Company in general meeting:
(a) financial statements relating to the period covered by the latest completed
financial year, and made up of a statement of profit and loss, a statement of
surplus and a statement of source and application of funds, made up to a date
not earlier than the date of the meeting by more than six months;
(b) a balance sheet as at the end of such period;
and
(c) the report of the auditor to the shareholders. Every statement of profit and
loss to be laid before the Company in general meeting shall be drawn up so as to
present fairly the results of the operation of the Company for the period
covered by the statement. Every statement of surplus to be laid before the
Company in general meeting shall be drawn up so as to present fairly the
transactions reflected in statement. The statement of source and application of
funds to be laid before the Company in general meeting shall be drawn up so as
to present fairly the information shown therein for the period. The balance
sheet to be laid before the Company in general meeting shall be drawn up so as
to present fairly the financial position of the Company as at the date to which
it is made up.
101. The Company shall, twenty-one days or more before the date of the general
meeting at which the financial statements are to be laid before the Company,
send by prepaid mail to each member at his latest address as shown on the
Register, a copy of the financial statements and a copy of the auditor's report.
-24-
<PAGE>
AUDITORS
102. The Company may at each annual general meeting appoint an Auditor or
Auditors to hold office from the conclusion of that, until the conclusion of the
next annual general meeting. At any annual general meeting a retiring Auditor,
however appointed, shall be re-appointed without any resolution being passed
unless:
(a) he is not qualified for re-appointment;
or
(b) a resolution has been passed at that meeting appointing somebody instead of
him or providing expressly that he shall not be re-appointed; or
(c) he has given the Company notice in writing of his unwillingness to be
re-appointed.
103. The Auditor shall make a report to the members on the accounts examined by
him, on every balance sheet and on every statement of profit and loss, statement
of surplus and statement of source and application of funds to be laid before
the Company in general meeting during his tenure of office, and his report,
which shall be open to inspection by any member shall contain statements as to
whether in his opinion the financial statements referred to therein present
fairly the financial position of the Company and the results of its operations
for the period under review in accordance with generally accepted accounting
principles applied on a basis consistent with that of the preceding period, and
shall also contain such statements as he considers necessary:
(a) if he has not obtained all the information and explanations which to the
best of his knowledge and belief were necessary for the purpose of his audit;
(b) if in his opinion, proper books of account have not been kept by the
Company, so far as appears from his examination of their books, and proper
returns adequate for the purpose of his audit have not been received from
branches not visited by him;
(c) (i) if the Company's balance sheet and statements of profit and loss,
surplus and source and application of funds dealt with by the report are not in
agreement with the books of accounts and returns;
(ii) if in his opinion and to the best of his information and according to the
explanations given to him, the said accounts do not give the information
-25-
<PAGE>
re-required by these presents in the manner so required and do not give a true
and fair view, in the case of the balance sheet, of the state of the Company's
affairs as at the date thereof, and in the case of the statements of profit and
loss, surplus and source and application of funds, of the information shown
therein of the Company for the period dealt with therein.
104. All acts done by any person acting as an Auditor shall as regards all
persons dealing in good faith with the Company, be valid, notwithstanding that
there was some defect in his appointment or that he was at the time of his
appointment not qualified for appointment.
105. The Auditor shall be entitled to attend any general meeting and receive all
notices of and other communications relating to any general meeting which any
member is entitled to receive, and to be heard at any general meeting on any
part of the business of the meeting which concerns him as Auditor.
NOTICES
106. Any notice or document may be sent to or served on any member or Director
either personally or by sending it through the post in a prepaid letter or by
telegram, cable or, telex addressed to such member or Director at his registered
address, or to the address, if any, supplied by him to the Company as his
address for the service of notices. Where a notice or other document is served
by post, service shall be deemed to be effected at the time when the letter
containing the same is posted, and where severed by telegram, cable or telex,
when the same is transmitted and in proving such service it shall be sufficient
to prove that such notice was properly addressed, and posted or transmitted as
the case may be. Provided that, for the purpose of serving notice of any meeting
of members of the Company on any member whose address as aforesaid is outside
the Bahama Islands, such method of posting is adopted as would in the ordinary
course result in such member receiving such notice at such address not less than
fourteen days in advance of the date fixed for the meeting but the Company shall
not be accountable for any accidental omission by any such member to receive any
such notice.
107. In respect of joint holdings all notices shall be given to that one of the
joint holders whose name stands first in the Register, and notice so given shall
be sufficient notice to all the joint holders.
108. A person entitled to a share in consequence of the death or bankruptcy of a
member, upon supplying to the Company such evidence as the Directors may
reasonably require to show his title to the share, and upon supplying also an
-26-
<PAGE>
address for the service of notices, shall be entitled to have served upon him at
such address any notice or document to which the member but for his death or
bankruptcy would be entitled, and such service shall for all purposes be deemed
a sufficient service of such notice or document on all persons interested
(whether jointly with or as claiming through or under him) in the share. Save as
aforesaid, any notice or document delivered or sent by post to, or left at the
registered address of any member in pursuance of these Articles shall,
notwithstanding that such member be then dead or bankrupt and where or not the
Company has notice of his death or bankruptcy, be deemed to have been duly
served in respect to any share registered in the name of such member as sole or
joint holder.
109. A member who has not supplied to the Company a registered address or an
address for the service of notices shall not be entitled to receive notices from
the Company.
WINDING UP
110. If the Company shall be wound up (whether the liquidation is voluntary,
under supervision, or by the Court) the Liquidator may, with the authority of a
Special Resolution, divide among the members in specie or kind the whole or any
part of the assets of the Company and whether or not the assets shall consist of
property of one kind or shall consist of properties of different kinds, and may
for such purpose set such value as he deems fair upon any one or more class or
classes of property and may determine, how such division shall be carried out as
between the members or different classes of members. The Liquidator may, with
the like authority, vest any part of the assets in trustees upon such trusts for
the benefit of members as the Liquidator with the like authority shall think
fit, and the liquidation of the Company may be closed and the Company dissolved.
INDEMNITY
111. Subject to the provisions of the Statute, every Director or officer of the
Company or other person who has undertaken or is about to undertake any
liability on behalf of the Company or any company controlled by it and their
heirs, executors and administrators and estate and effects, respectively, shall
from time to time and at all times be indemnified and saved harmless out of the
funds of the Company, from and against:
(a) all costs, charges and expenses whatsoever which such Director, officer or
other person sustains or incurs in or about any action, suit or proceeding which
is brought, commenced or prosecuted against him, for or in respect of any act,
deed, matter or thing whatsoever, made, done or permitted by him in or about the
-27-
<PAGE>
execution of the duties of his office or in respect of any such liability;
(b) all other costs, charges and expenses which he sustains or incurs in or
about or in relation to the affairs thereof, except such costs, charges or
expenses as are occasioned by his own wilfulness, neglect or default. The amount
for which such indemnity is provided shall immediately attach as a lien on the
property of the Company and shall have priority over any claims of the Company
or any member.
112. No Director or officer shall be liable for the acts, receipts, neglects, or
defaults of any other Director or officer, or for joining in any receipt or
other act for conformity, or for any loss or expense incurred by the Company as
a result of insufficiency or deficiency of title to any property acquired by
order of the Directors for or on behalf of the Company, or for the insufficiency
or deficiency of any security in or upon which any of the moneys of the Company
shall be advanced or invested, or for any loss or damage arising out of the
bankruptcy, insolvency or tortious or criminal act or omission of any person
with whom any moneys, securities or effects shall be deposited, or for any loss
occasioned by an error of judgment, omission, default, or oversight on his part,
or for any other loss, damage or misfortune whatever which shall happen in the
execution of his office or in relation thereto, except the same shall happen
through his own dishonesty.
IN WITNESS WHEREOF we, the Subscribers to the Articles of Association have
hereunto subscribed our names this 12th day of June A.D. 1979.
Carey Leonard
Carol Ann Weatherford
Joan Mackey
Cypriana Burrows
Donna Wright
Signed by the Subscribers to the Articles of Association in the presence of:
/s/ Sean McWeeney
COMMONWEALTH OF THE BAHAMAS
New Providence
I, Sean McWeeney of Nassau, Bahamas make oath and say that I was present and
saw:
Carey Leonard
Carol Ann Weatherford
Joan Mackey
Cypriana Burrows
Donna Wright
-28-
<PAGE>
all of the said Island of New Providence sign and as and for their Act execute
the foregoing Articles of Association dated the 12th day of June A.D. 1979 for
the purposes therein mentioned; and that I subscribed my name as the witness to
the due execution thereof.
SWORN to this 13th day of June A.D. 1979
Before me,
R.D. Seligman
NOTARY PUBLIC
-29-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> JAN-31-2000
<PERIOD-START> FEB-01-1999
<PERIOD-END> JUL-31-1999
<CASH> 304,000
<SECURITIES> 0
<RECEIVABLES> 1,268,471
<ALLOWANCES> 0
<INVENTORY> 1,989,409
<CURRENT-ASSETS> 3,607,444
<PP&E> 9,310,324
<DEPRECIATION> 4,763,632
<TOTAL-ASSETS> 10,447,900
<CURRENT-LIABILITIES> 1,799,075
<BONDS> 501,981
0
15,010
<COMMON> 48,852
<OTHER-SE> 22,538,271
<TOTAL-LIABILITY-AND-EQUITY> 10,447,900
<SALES> 6,197,926
<TOTAL-REVENUES> 6,197,926
<CGS> 4,389,648
<TOTAL-COSTS> 4,389,648
<OTHER-EXPENSES> 1,348,021
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 71,387
<INCOME-PRETAX> 405,170
<INCOME-TAX> 201,690
<INCOME-CONTINUING> 203,480
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 203,480
<EPS-BASIC> 0.07
<EPS-DILUTED> 0.07
</TABLE>
